FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Swiss pharmaceutical giant Novartis (SIX:NOVN) has reaffirmed its commitment to producing life-saving treatments for malaria and leprosy, even amid uncertainty over global health funding. According to Dr. Lutz Hegemann, President of Global Health at Novartis, the company will continue manufacturing its 28 million annual malaria treatment courses regardless of demand or funding disruptions.
Most of Novartis' antimalarial drugs are sold at a not-for-profit price to global initiatives, including the U.S.-funded President’s Malaria Initiative (PMI). However, recent aid cuts under President Donald Trump have threatened such programs. Earlier this year, a contractor for PMI canceled an order due to a government stop-work directive, but resumed the request shortly after receiving an exemption. “We are not going to be the bottleneck,” said Hegemann, emphasizing the company's commitment to maintaining supply even during funding gaps.
The Global Fund to Fight AIDS, Tuberculosis and Malaria remains the largest purchaser of Novartis' malaria treatments. While it has not yet faced funding cuts, it is actively seeking donations in a difficult financial environment.
Speaking from London, Hegemann urged the pharmaceutical industry to take a more proactive role in global health, advocating for deeper collaborations with low- and middle-income countries. He stressed that companies should go beyond merely compensating for shrinking donor aid and instead foster long-term public-private partnerships.
Novartis is also ramping up its R&D spending on malaria and neglected tropical diseases. The company expects to invest $490 million by 2025—nearly double its original $250 million pledge. Ongoing projects include a dengue antiviral, new therapies for leishmaniasis and Chagas disease, and the first malaria drug designed for newborns.
This strong commitment highlights Novartis’ leadership in global health and its resolve to support vulnerable communities worldwide.
